Department of Mechanical Engineering, KU Leuven - University of Leuven, 3001, Heverlee, Belgium.
Department of Ophthalmology, KU Leuven - University Hospitals Leuven, 3000, Leuven, Belgium.
Ann Biomed Eng. 2018 Oct;46(10):1676-1685. doi: 10.1007/s10439-018-2053-3. Epub 2018 May 24.
Retinal Vein Occlusion (RVO) is a blinding disease caused by one or more occluded retinal veins. Current treatment methods only focus on symptom mitigation rather than targeting a solution for the root cause of the disorder. Retinal vein cannulation is an experimental eye surgical procedure which could potentially cure RVO. Its goal is to dissolve the occlusion by injecting an anticoagulant directly into the blocked vein. Given the scale and the fragility of retinal veins on one end and surgeons' limited positioning precision on the other, performing this procedure manually is considered to be too risky. The authors have been developing robotic devices and instruments to assist surgeons in performing this therapy in a safe and successful manner. This work reports on the clinical translation of the technology, resulting in the world-first in-human robot-assisted retinal vein cannulation. Four RVO patients have been treated with the technology in the context of a phase I clinical trial. The results show that it is technically feasible to safely inject an anticoagulant into a [Formula: see text]-thick retinal vein of an RVO patient for a period of 10 min with the aid of the presented robotic technology and instrumentation.
视网膜静脉阻塞 (RVO) 是一种致盲性疾病,由一条或多条阻塞的视网膜静脉引起。目前的治疗方法仅侧重于缓解症状,而不是针对该疾病的根本原因。视网膜静脉插管是一种实验性的眼部手术程序,有可能治愈 RVO。其目的是通过直接将抗凝剂注入阻塞的静脉来溶解阻塞。鉴于一端的视网膜静脉的规模和脆弱性以及另一端外科医生有限的定位精度,手动执行此程序被认为风险太大。作者一直在开发机器人设备和仪器,以协助外科医生以安全且成功的方式进行这种治疗。这项工作报告了该技术的临床转化,实现了世界首例机器人辅助视网膜静脉插管的人体临床试验。在一项 I 期临床试验中,已经使用该技术对 4 名 RVO 患者进行了治疗。结果表明,借助所提出的机器人技术和仪器,在 10 分钟的时间内安全地将抗凝剂注入 RVO 患者的 [Formula: see text]-厚视网膜静脉中在技术上是可行的。